

20 OCTOBER 2021

THAILAND / HEALTHCARE

PRARAM 9 HOSPITAL PR9 TB

BUY

UNCHANGED

TARGET PRICE	THB14.00
CLOSE	THB11.00
UP/DOWNSIDE	+27.3%
PRIOR TP	THB14.00
CHANGE IN TP	UNCHANGED
TP vs CONSENSUS	+19.7%

When revenue flows, earnings jump

3Q21 should be the best quarter for PR9 during the pandemic

We expect 3Q21 revenue to grow by 10% y-y and 20% q-q, led by Covid-related revenue during July-Aug and the return of non-Covid patients in Sep. Covid-related revenue should have peaked in Aug with Covid patients in hospitals and hospitelts averaging around 100 beds/day (vs PR9's hospital capacity of 225 beds) before gradually declining to 40-50 beds/day in Sep. As a result, Covid-related revenue should account for about 10-15% of the total revenue in 3Q21 (vs 6% in 2Q21). On a positive note, the Thai non-Covid patient volume started to recover in Sep and should be the key driver for an improving EBITDA margin that we estimate at 22% in 3Q21 (from 13% in 2Q21 and 20% in 3Q20). Overall, we expect 3Q21 earnings to grow by 14% y-y to THB83m.

Growth of non-Covid patients to resume in 4Q21

Although Covid-related services should slow down in 4Q21, non-Covid patients should continue to recover, driven by 1) kidney transplant cases – the number of cases had not yet returned to the pre-Covid level in 3Q21; 2) health check-ups which were postponed from 2Q-3Q21; and 3) new medical centres, including the Lasik Centre, Advanced Spine Centre, and the Oncology Centre. Thus, we estimate that its core profit maintains its momentum above cTHB80m in 4Q21.

Strong earnings growth from high operating leverage


PR9's earnings were volatile over the past few quarters. The company had recently invested in new buildings and medical centres and revenue had just surpassed the breakeven point, especially in terms of doctor fees. PR9 has to pay a minimum guarantee to doctors in case revenue is lower than its commitment. However, it will turn to revenue sharing if revenue surpasses the threshold. We see this as a positive given that larger revenue from this point on would almost flow directly to the bottom line since most expenses are fixed costs. As a result, we forecast revenue to grow by 22% and earnings to jump 82% in 2022, while we expect the EBITDA margin to rise from 19% in 2021 to 23% in 2023.

Deserves to trade at a premium to its IPO price

PR9 is trading at an attractive 24x 2022E P/E, lower than its peers' average of 34x. We think its share price deserves to trade at a premium to its IPO price of THB11.6/shr, as we expect its EBITDA in 2022 to exceed the 2019 level by 36%.

KEY STOCK DATA

YE Dec (THB m)	2020	2021E	2022E	2023E
Revenue	2,601	2,759	3,360	3,756
Net profit	202	198	359	465
EPS (THB)	0.26	0.25	0.46	0.59
vs Consensus (%)	-	(8.4)	23.3	26.9
EBITDA	444	535	732	875
Core net profit	202	198	359	465
Core EPS (THB)	0.26	0.25	0.46	0.59
Chg. In EPS est. (%)	-	-	-	-
EPS growth (%)	(35.3)	(2.1)	81.5	29.5
Core P/E (x)	42.8	43.7	24.1	18.6
Dividend yield (%)	1.0	1.4	2.9	3.8
EV/EBITDA (x)	18.2	14.9	10.7	8.6
Price/book (x)	2.1	2.0	1.9	1.8
Net debt/Equity (%)	(14.2)	(15.5)	(18.3)	(23.4)
ROE (%)	5.0	4.7	8.3	10.2



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	1.9	0.9	61.8
Relative to country (%)	1.6	(3.7)	19.9
Mkt cap (USD m)	260		
3m avg. daily turnover (USD m)	0.4		
Free float (%)	59		
Major shareholder	Khunying Potjaman Damapong (37%)		
12m high/low (THB)	11.90/6.80		
Issued shares (m)	786.30		

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA

 teerapol.udo@fssia.com
 +66 2611 3535

Investment thesis

PR9 is a standalone hospital that is known as a “value-for-money” hospital. It recently upgraded the hospital to include tertiary care with new specialist centres. One of the top contributors is the Kidney Transplant Institute, which is the only facility to be accredited by Joint Commission International (JCI) outside the US.

The hospital is in a growth phase, with its new building having opened in July 2020. Although the market is concerned about the new building’s drag on its overall operations, we believe this should strengthen PR9 in the long term.

The improving EBITDA margin should lead to its stock re-rating, and its share price should exceed its IPO price of THB11.6 when it becomes apparent that the new building will support its earnings, in our view.


Company profile

PR9 has been operating a private hospital since 1992.

www.praram9.com

Principal activities (revenue, 2020)


- OPD patient revenue - 56.2 %
- IPD patient revenue - 43.8 %



Source: Praram 9 Hospital

Major shareholders

- Khunying Potjaman Damapong - 37.1 %
- Standard Life Aberdeen PLC - 2.1 %
- Bualuang Basic Dividend LTF - 1.6 %
- Dr. Satian Pooprasert - 1.3 %
- Others - 57.9 %



Source: Praram 9 Hospital

Catalysts

Key potential growth drivers include 1) a higher Thai patient volume from new specialist centres; and 2) rising demand for medical tourists, especially patients from Cambodia, Laos, Myanmar and Vietnam (CLMV), as well as China.

Risks to our call

Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Event calendar

Date	Event
Nov 2021	3Q21 results announcement

Key assumptions

	2021E	2022E	2023E
	(%)	(%)	(%)
No. of licensed beds (no.)	190	215	249
OPD volume growth	4	16	8
OPD revenue / patient growth	3	5	4
IPD volume growth	3	16	8
IPD revenue / patient growth	2	5	4


Source: FSSIA estimates

Earnings sensitivity

- For every 1% increase in patient volume, we project 2021 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2021 earnings to rise by 14%, and vice versa, all else being equal.


Source: FSSIA estimates

Exhibit 1: Core profit, quarterly




Sources: PR9; FSSIA estimates

Exhibit 2: EBITDA, quarterly




Sources: PR9; FSSIA estimates

Exhibit 3: EBITDA margin, quarterly




Sources: PR9; FSSIA estimates

Exhibit 4: EBITDA margin upward trend over next three years




Sources: PR9; FSSIA estimates

Exhibit 5: COGS breakdown as of 2020



Sources: PR9; FSSIA estimates

Exhibit 6: SG&A expenses have been stable over the past few quarters




Sources: PR9; FSSIA estimates

Exhibit 7: 3Q21E results preview

FY ending Dec	3Q20	4Q20	1Q21	2Q21	3Q21E	----- Change -----		9M20	9M21E	Change	2021E
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)	(THB m)
Sales	692	735	669	632	761	20	10	1,866	2,062	10	2,759
COGS (incl depreciation)	(485)	(520)	(502)	(500)	(536)	7	11	(1,370)	(1,539)	12	(2,022)
Gross profit	207	215	166	132	224	70	9	496	523	5	737
SG&A	(132)	(132)	(132)	(130)	(136)	5	3	(387)	(398)	3	(534)
Operating profit	75	83	34	2	88	4,315	19	110	125	14	203
Net other income	9	12	11	11	11	(2)	20	25	33	30	41
Interest expenses	(0)	(0)	(0)	(0)	0	(100)	(100)	(0)	(0)	n/a	(0)
Pretax profit	84	96	45	13	99	661	19	135	157	17	244
Income tax	(11)	(14)	(6)	(1)	(17)	1,222	48	(14)	(25)	78	(46)
Core profit	72	81	39	12	83	600	14	121	133	10	198
Extraordinaries, GW & FX											
Reported net profit	72	81	39	12	83	600	14	121	133	10	198
Outstanding shares (m)	786	786	786	786	786	0	0	786	786	0	786
Pre-ex EPS (THB)	0.09	0.10	0.05	0.01	0.10	600	14	0.15	0.17	10	0.25
EPS (THB)	0.09	0.10	0.05	0.01	0.10	600	14	0.15	0.17	10	0.25
COGS excl. depreciation	(425)	(455)	(431)	(428)	(463)	8	9	(1,222)	(1,322)	8	(1,731)
Depreciation	(60)	(65)	(71)	(72)	(73)	1	22	(148)	(217)	46	(290)
EBITDA	144	161	116	85	172	102	20	283	374	32	535
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)	(%)
Gross margin	30	29	25	21	30	9	(0)	27	25	(1)	27
SG&A/Revenue	19	18	20	21	18	(3)	(1)	21	19	(1)	19
EBITDA margin	20	21	17	13	22	9	2	15	18	3	19
Net profit margin	10	11	6	2	11	9	0	6	6	(0)	7
Operating stats	(%)	(%)	(%)	(%)							
OPD revenue growth y-y	(8)	4	(4)	29							
OPD volume growth y-y	(9)	-	(10)	16							
OPD revenue per head growth y-y	1	4	6	11							
IPD revenue growth y-y	(6)	(7)	9	16							
IPD volume growth y-y	(17)	(8)	1	37							
IPD revenue per head growth y-y	13	2	8	(15)							
Thai patient revenue growth y-y	3	6	10	19							
Inter patient revenue growth y-y	(60)	(53)	(46)	81							


Sources: PR9; FSSIA estimate

Exhibit 8: Historical P/E band



Sources: Bloomberg; FSSIA estimates

Exhibit 9: Historical P/BV band



Sources: Bloomberg; FSSIA estimates

Exhibit 10: Peer comparisons as of 19 Oct 2021

Company	BBG	Rec	Share price			Market Cap (USD m)	PE		ROE		PBV		EV/EBITDA	
			Current (LCY)	Target (LCY)	Upside (%)		21E (x)	22E (x)	21E (%)	22E (%)	21E (x)	22E (x)	21E (x)	22E (x)
Thailand														
Bangkok Dusit Med Service	BDMS TB	BUY	23.20	29.00	25.0	11,064	53.4	36.5	8.1	11.6	4.4	4.1	23.7	18.2
Bumrungrad Hospital	BH TB	BUY	143.00	155.00	8.4	3,410	119.1	48.2	5.4	13.2	6.7	6.1	46.6	25.8
Bangkok Chain Hospital	BCH TB	BUY	20.40	28.50	39.7	1,527	12.0	27.6	48.6	17.8	4.8	5.0	8.1	15.5
Chularat Hospital	CHG TB	BUY	3.74	4.70	25.7	1,235	23.9	32.5	37.3	23.8	7.9	7.6	16.0	20.5
Praram 9 Hospital	PR9 TB	BUY	11.00	14.00	27.3	260	43.7	24.1	4.7	8.3	2.0	1.9	14.9	10.7
Thonburi Healthcare Group	THG TB	HOLD	33.25	27.50	(17.3)	842	98.1	67.8	3.6	5.2	3.6	3.5	27.8	25.1
Vibhavadi Medical Center	VIBHA TB	BUY	2.22	2.80	26.1	904	46.6	37.4	8.6	8.8	3.6	2.7	28.5	24.4
Ramkhamhaeng Hospital	RAM TB	BUY	168.00	225.00	33.9	1,210	23.7	23.0	13.6	13.9	3.3	3.1	16.3	16.2
Rajthanee Hospital	RJH TB	n/a	33.00	n/a	n/a	291	15.4	20.7	39.2	27.0	6.6	5.7	10.6	13.4
Ekachai Medical Care	EKH TB	n/a	7.95	n/a	n/a	143	19.2	25.8	25.4	18.9	5.5	4.9	12.0	14.5
Thailand average						20,884	45.5	34.4	19.5	14.8	4.8	4.5	20.4	18.4
Regional														
Ramsay Health Care	RHC AU	n/a	66.75	n/a	n/a	11,410	32.5	29.8	11.3	12.1	3.7	3.7	12.6	11.8
Ihh Healthcare Bhd	IHH SP	n/a	2.17	n/a	n/a	14,182	44.5	38.9	5.7	6.1	2.5	2.5	17.7	16.6
Ryman Healthcare	RYM NZ	n/a	14.70	n/a	n/a	5,264	31.6	25.5	12.2	9.0	3.2	2.9	35.1	25.9
Apollo Hospitals Enterprise	APHS IN	n/a	4,301	n/a	n/a	8,217	720.3	74.1	2.4	15.8	17.0	14.7	56.6	30.6
Kpj Healthcare Berhad	KPJ MK	n/a	1.12	n/a	n/a	1,155	58.9	26.7	4.1	8.7	2.5	2.2	16.2	12.2
Raffles Medical Group	RFMD SP	n/a	1.55	n/a	n/a	2,155	37.8	36.9	8.4	8.7	3.3	3.1	21.0	19.8
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,250	n/a	n/a	2,274	28.9	30.4	20.9	18.1	6.6	5.6	18.0	19.2
Aier Eye Hospital Group	300015 CH	n/a	47.18	n/a	n/a	39,952	102.6	78.0	20.6	22.5	29.9	20.6	60.2	47.8
Regional average						84,609	132.1	42.5	10.7	12.6	8.6	6.9	29.7	23.0
Overall average						105,493	84.0	38.0	15.6	13.9	6.5	5.6	24.5	20.5

Sources: Bloomberg; FSSIA estimates

Financial Statements

Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2019	2020	2021E	2022E	2023E
Revenue	2,849	2,601	2,759	3,360	3,756
Cost of goods sold	(1,792)	(1,677)	(1,731)	(2,092)	(2,305)
Gross profit	1,056	925	1,027	1,268	1,451
Other operating income	41	38	41	43	45
Operating costs	(558)	(518)	(534)	(579)	(621)
Operating EBITDA	540	444	535	732	875
Depreciation	(165)	(213)	(290)	(289)	(301)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	375	231	244	443	574
Net financing costs	0	0	0	0	0
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	(28)	0	0	0	0
Profit before tax	348	230	244	443	574
Tax	(63)	(28)	(46)	(84)	(109)
Profit after tax	284	202	198	359	465
Minority interests	0	0	0	0	0
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	284	202	198	359	465
Non-recurring items & goodwill (net)	28	0	0	0	0
Recurring net profit	312	202	198	359	465
Per share (THB)					
Recurring EPS *	0.40	0.26	0.25	0.46	0.59
Reported EPS	0.36	0.26	0.25	0.46	0.59
DPS	0.14	0.11	0.15	0.32	0.41
Diluted shares (used to calculate per share data)	786	786	786	786	786
Growth					
Revenue (%)	5.5	(8.7)	6.1	21.8	11.8
Operating EBITDA (%)	11.7	(17.8)	20.5	36.8	19.6
Operating EBIT (%)	14.5	(38.5)	5.9	81.4	29.4
Recurring EPS (%)	16.0	(35.3)	(2.1)	81.5	29.5
Reported EPS (%)	80.9	(29.0)	(2.1)	81.5	29.5
Operating performance					
Gross margin inc. depreciation (%)	31.3	27.4	26.7	29.2	30.6
Gross margin of key business (%)	31.3	27.4	26.7	29.2	30.6
Operating EBITDA margin (%)	19.0	17.1	19.4	21.8	23.3
Operating EBIT margin (%)	13.2	8.9	8.9	13.2	15.3
Net margin (%)	11.0	7.8	7.2	10.7	12.4
Effective tax rate (%)	16.8	12.3	19.0	19.0	19.0
Dividend payout on recurring profit (%)	35.3	42.8	60.0	70.0	70.0
Interest cover (X)	-	491.0	1,040.3	1,887.2	2,442.7
Inventory days	9.3	10.7	10.6	9.8	10.2
Debtor days	18.9	22.1	21.2	17.8	16.3
Creditor days	88.6	98.8	95.6	88.8	92.7
Operating ROIC (%)	13.6	6.4	5.4	9.6	12.4
ROIC (%)	12.8	6.3	5.3	9.5	12.2
ROE (%)	7.9	5.0	4.7	8.3	10.2
ROA (%)	6.8	4.3	4.1	7.0	8.6
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)					
OPD patient revenue	1,584	1,461	1,561	1,901	2,125
IPD patient revenue	1,264	1,140	1,198	1,459	1,631

Sources: Praram 9 Hospital; FSSIA estimates

Financial Statements

Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2019	2020	2021E	2022E	2023E
Recurring net profit	312	202	198	359	465
Depreciation	165	213	290	289	301
Associates & minorities	-	-	-	-	-
Other non-cash items	21	98	0	0	0
Change in working capital	51	(435)	(12)	(2)	(9)
Cash flow from operations	548	78	476	646	757
Capex - maintenance	(885)	(806)	(321)	(363)	(228)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	0	0	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(885)	(806)	(321)	(363)	(228)
Dividends paid	(112)	(110)	(86)	(119)	(251)
Equity finance	0	0	0	0	0
Debt finance	0	8	0	0	0
Other financing cash flows	19	(8)	0	0	0
Cash flow from financing	(92)	(110)	(86)	(119)	(251)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	(429)	(839)	69	164	278
Free cash flow to firm (FCFF)	(336.83)	(727.76)	155.58	282.55	529.48
Free cash flow to equity (FCFE)	(317.56)	(728.33)	155.35	282.32	529.24

Per share (THB)

FCFF per share	(0.43)	(0.93)	0.20	0.36	0.67
FCFE per share	(0.40)	(0.93)	0.20	0.36	0.67
Recurring cash flow per share	0.63	0.65	0.62	0.82	0.97

Balance Sheet (THB m) Year Ending Dec	2019	2020	2021E	2022E	2023E
Tangible fixed assets (gross)	4,559	5,345	5,666	6,029	6,257
Less: Accumulated depreciation	(1,619)	(1,812)	(2,102)	(2,391)	(2,692)
Tangible fixed assets (net)	2,940	3,533	3,564	3,639	3,565
Intangible fixed assets (net)	0	0	0	0	0
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	4	4	4	4	4
Cash & equivalents	1,431	592	661	825	1,103
A/C receivable	156	159	162	165	169
Inventories	49	49	51	61	68
Other current assets	7	408	433	527	589
Current assets	1,643	1,208	1,307	1,579	1,929
Other assets	130	52	52	52	52
Total assets	4,717	4,797	4,926	5,272	5,549
Common equity	4,039	4,115	4,226	4,467	4,680
Minorities etc.	0	0	0	0	0
Total shareholders' equity	4,039	4,115	4,226	4,467	4,680
Long term debt	0	8	8	8	8
Other long-term liabilities	155	182	182	182	182
Long-term liabilities	155	190	190	190	190
A/C payable	461	446	461	557	613
Short term debt	0	0	0	0	0
Other current liabilities	62	45	48	59	66
Current liabilities	523	492	509	615	679
Total liabilities and shareholders' equity	4,717	4,797	4,926	5,272	5,549
Net working capital	(311)	124	136	138	147
Invested capital	2,763	3,713	3,755	3,832	3,767

* Includes convertibles and preferred stock which is being treated as debt

Per share (THB)

Book value per share	5.14	5.23	5.38	5.68	5.95
Tangible book value per share	5.14	5.23	5.38	5.68	5.95

Financial strength

Net debt/equity (%)	(35.4)	(14.2)	(15.5)	(18.3)	(23.4)
Net debt/total assets (%)	(30.3)	(12.2)	(13.3)	(15.5)	(19.7)
Current ratio (x)	3.1	2.5	2.6	2.6	2.8
CF interest cover (x)	-	(1,548.6)	662.2	1,202.7	2,253.7

Valuation	2019	2020	2021E	2022E	2023E
Recurring P/E (x) *	27.7	42.8	43.7	24.1	18.6
Recurring P/E @ target price (x) *	35.3	54.5	55.7	30.7	23.7
Reported P/E (x)	30.4	42.8	43.7	24.1	18.6
Dividend yield (%)	1.3	1.0	1.4	2.9	3.8
Price/book (x)	2.1	2.1	2.0	1.9	1.8
Price/tangible book (x)	2.1	2.1	2.0	1.9	1.8
EV/EBITDA (x) **	13.4	18.2	14.9	10.7	8.6
EV/EBITDA @ target price (x) **	17.7	23.5	19.4	13.9	11.3
EV/invested capital (x)	2.6	2.2	2.1	2.0	2.0

* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income

Sources: Praram 9 Hospital; FSSIA estimates

Corporate Governance report of Thai listed companies 2020

EXCELLENT LEVEL										
AAV	ADVANC	AF	AIRA	AKP	AKR	ALT	AMA	AMATA	AMATAV	ANAN
AOT	AP	ARIP	ARROW	ASP	BAFS	BANPU	BAY	BCP	BCPG	BDMS
BEC	BEM	BGRIM	BIZ	BKI	BLA	BOL	BPP	BRR	BTS	BWG
CENTEL	CFRESH	CHEWA	CHO	CIMBT	CK	CKP	CM	CNT	COL	COMAN
COTTO	CPALL	CPF	CPI	CPN	CSS	DELTA	DEMCO	DRT	DTAC	DTC
DV8	EA	EASTW	ECF	ECL	EGCO	EPG	ETE	FNS	FPI	FPT
FSMART	GBX	GC	GCAP	GEL	GFPT	GGC	GPSC	GRAMMY	GUNKUL	HANA
HARN	HMPRO	ICC	ICI	III	ILINK	INTUCH	IRPC	IVL	JKN	JSP
JWD	K	KBANK	KCE	KKP	KSL	KTB	KTC	LANNA	LH	LHFG
LIT	LPN	MAKRO	MALEE	MBK	MBKET	MC	MCOT	METCO	MFEC	MINT
MONO	MOONG	MSC	MTC	NCH	NCL	NEP	NKI	NOBLE	NSI	NVD
NYT	OISHI	ORI	OTO	PAP	PCSGH	PDJ	PG	PHOL	PLANB	PLANET
PLAT	PORT	PPS	PR9	PREB	PRG	PRM	PSH	PSL	PTG	PTT
PTTEP	PTTGC	PYLON	Q-CON	QH	QTC	RATCH	RS	S	S & J	SAAM
SABINA	SAMART	SAMTEL	SAT	SC	SCB	SCC	SCCC	SCG	SCN	SDC
SEAFCO	SEAOIL	SE-ED	SELIC	SENA	SIRI	SIS	SITHAI	SMK	SMPC	SNC
SONIC	SORKON	SPALI	SPI	SPRC	SPVI	SSSC	SST	STA	SUSCO	SUTHA
SVI	SYMC	SYNTEC	TACC	TASCO	TCAP	TFMAMA	THANA	THANI	THCOM	THG
THIP	THRE	THREL	TIP	TIPCO	TISCO	TK	TKT	TTB	TMILL	TNDT
TNL	TOA	TOP	TPBI	TQM	TRC	TRC	TSC	TSR	TSTE	TSTH
TTCL	TTW	TU	TVD	TVI	TVO	TWPC	U	UAC	UBIS	UV
VGI	VIH	WACOAL	WAVE	WHA	WHAUP	WICE	WINNER	TRUE		

VERY GOOD LEVEL										
2S	ABM	ACE	ACG	ADB	AEC	AEONTS	AGE	AH	AHC	AIT
ALLA	AMANAHA	AMARIN	APCO	APCS	APURE	AQUA	ASAP	ASEFA	ASIA	ASIAN
ASIMAR	ASK	ASN	ATP30	AUCT	AWC	AYUD	B	BA	BAM	BBL
BFIT	BGC	BJC	BJCHI	BROOK	BTW	CBG	CEN	CGH	CHARAN	CHAYO
CHG	CHOTI	CHOW	CI	CIG	CMC	COLOR	COM7	CPL	CRC	CRD
CSC	CSP	CWT	DCC	DCON	DDD	DOD	DOHOME	EASON	EE	ERW
ESTAR	FE	FLOYD	FN	FORTH	FSS	FTE	FVC	GENCO	GJS	GL
GLAND	GLOBAL	GLOCON	GPI	GULF	GYT	HPT	HTC	ICN	IFS	ILM
IMH	INET	INSURE	IRC	IRCP	IT	ITD	ITEL	J	JAS	JCK
JCKH	JMART	JMT	KBS	KCAR	KGI	KIAT	KOOL	KTIS	KWC	KWM
L&E	LALIN	LDC	LHK	LOXLEY	LPH	LRH	LST	M	MACO	MAJOR
MBAX	MEGA	META	MFC	MGT	MILL	MITSIB	MK	MODERN	MTI	MVP
NETBAY	NEX	NINE	NTV	NWR	OCC	OGC	OSP	PATO	PB	PDG
PDI	PICO	PIMO	PJW	PL	PM	PPP	PRIN	PRINC	PSTC	PT
QLT	RCL	RICHY	RML	RPC	RWI	S11	SALEE	SAMCO	SANKO	SAPPE
SAWAD	SCI	SCP	SE	SEG	SFP	SGF	SHR	SIAM	SINGER	SKE
SKR	SKY	SMIT	SMT	SNP	SPA	SPC	SPCG	SR	SRICHA	SSC
SSF	STANLY	STI	STPI	SUC	SUN	SYNEX	T	TAE	TAKUNI	TBSP
TCC	TCMC	TEAM	TEAMG	TFG	TIGER	TITLE	TKN	TKS	TM	TMC
TMD	TMI	TMT	TNITY	TNP	TNR	TOG	TPA	TPAC	TPCORP	TPOLY
TPS	TRITN	TRT	TRU	TSE	TVT	TWP	UEC	UMI	UOBKH	UP
UPF	UPOIC	UT	UTP	UWC	VL	VNT	VPO	WIJK	WP	XO
YUASA	ZEN	ZIGA	ZMICO							

GOOD LEVEL										
7UP	A	ABICO	AJ	ALL	ALUCON	AMC	APP	ARIN	AS	AU
B52	BC	BCH	BEAUTY	BGT	BH	BIG	BKD	BLAND	BM	BR
BROCK	BSBM	BSM	BTNC	CAZ	CCP	CGD	CITY	CMAN	CMO	CMR
CPT	CPW	CRANE	CSR	D	EKH	EP	ESSO	FMT	GIFT	GREEN
GSC	GTB	HTECH	HUMAN	IHL	INOX	INSET	IP	JTS	JUBILE	KASET
KCM	KKC	KUMWEL	KUN	KWG	KYE	LEE	MATCH	MATI	M-CHAI	MCS
MDX	MJD	MM	MORE	NC	NDR	NER	NFC	NNCL	NPK	NUSA
OCEAN	PAF	PF	PK	PLE	PMTA	POST	PPM	PRAKIT	PRECHA	PRIME
PROUD	PTL	RBF	RCI	RJH	ROJNA	RP	RPH	RSP	SF	SFLEX
SGP	SISB	SKN	SLP	SMART	SOLAR	SPG	SQ	SSP	STARK	STC
SUPER	SVOA	TC	TCCC	THMUI	TIW	TNH	TOPP	TPCH	TIPIP	TPLAS
TTI	TYCN	UKEM	UMS	VCOM	VRANDA	WIN	WORK	WPH		

Description

Score Range

Excellent

90-100

Very Good

80-89

Good

70-79

Disclaimer:

The disclosure of the survey results of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey results may be changed after that date. FSS International Investment Advisory Company Limited does not confirm nor certify the accuracy of such survey results.

* CGR scoring should be considered with news regarding wrong doing of the company or director or executive of the company such unfair practice on securities trading, fraud, and corruption SEC imposed a civil sanction against insider trading of director and executive; ** delisted

Source: Thai Institute of Directors Association (IOD); FSSIA's compilation

Anti-corruption Progress Indicator 2020

CERTIFIED										
2S	ADVANC	AI	AIE	AIRA	AKP	AMA	AMANAHA	AP	AQUA	ARROW
ASK	ASP	AYUD	B	BAFS	BANPU	BAY	BBL	BCH	BCP	BCPG
BGC	BGRIM	BJCHI	BKI	BLA	BPP	BROOK	BRR	BSBM	BTS	BWG
CEN	CENTEL	CFRESH	CGH	CHEWA	CHOTI	CHOW	CIG	CIMBT	CM	CMC
COL	COM7	CPALL	CPF	CPI	CPN	CSC	DCC	DELTA	DEMCO	DIMET
DRT	DTAC	DTC	EASTW	ECL	EGCO	FE	FNS	FPI	FPT	FSS
FTE	GBX	GC	GCAP	GEL	GFPT	GGC	GJS	GPSC	GSTEEL	GUNKUL
HANA	HARN	HMPRO	HTC	ICC	ICHI	IFS	INET	INSURE	INTUCH	IRPC
ITEL	IVL	K	KASET	KBANK	KBS	KCAR	KCE	KGI	KKP	KSL
KTB	KTC	KWC	L&E	LANNA	LHFG	LHK	LPN	LRH	M	MAKRO
MALEE	MBAX	MBK	MBKET	MC	MCOT	MFC	MFEC	MINT	MONO	MOONG
MPG	MSC	MTC	MTI	NBC	NEP	NINE	NKI	NMG	NNCL	NSI
NWR	OCC	OCEAN	OGC	ORI	PAP	PATO	PB	PCSGH	PDG	PDI
PDJ	PE	PG	PHOL	PL	PLANB	PLANET	PLAT	PM	PPP	PPPM
PPS	PREB	PRG	PRINC	PRM	PSH	PSL	PSTC	PT	PTG	PTT
PTTEP	PTTGC	PYLON	Q-CON	QH	QLT	QTC	RATCH	RML	RWI	S & J
SABINA	SAT	SC	SCB	SCC	SCCC	SCG	SCN	SEAOIL	SE-ED	SELIC
SENA	SGP	SIRI	SITHAI	SMIT	SMK	SMPC	SNC	SNP	SORKON	SPACK
SPC	SPI	SPRC	SRICHA	SSF	SSSC	SST	STA	SUSCO	SVI	SYNTEC
TAE	TAKUNI	TASCO	TBSP	TCAP	TCMC	TFG	TFI	TFMAMA	THANI	THCOM
THIP	THRE	THREL	TIP	TIPCO	TISCO	TKT	TTB	TMD	TMILL	TMT
TNITY	TNL	TNP	TNR	TOG	TOP	TPA	TPCORP	TPP	TRU	TSC
TSTH	TTCL	TU	TVD	TVI	TVO	TWPC	U	UBIS	UEC	UKEM
UOBKH	UWC	VGI	VIH	VNT	WACOAL	WHA	WHAUP	WICE	WIJK	XO
ZEN	TRUE									

DECLARED										
7UP	ABICO	AF	ALT	AMARIN	AMATA	AMATAV	ANAN	APURE	B52	BKD
BM	BROCK	BUI	CHO	CI	COTTO	DDD	EA	EFORL	EP	ERW
ESTAR	ETE	EVER	FSMART	GPI	ILINK	IRC	J	JKN	JMART	JMT
JSP	JTS	KWG	LDC	MAJOR	META	NCL	NOBLE	NOK	PK	PLE
ROJNA	SAAM	SAPPE	SCI	SE	SHANG	SINGER	SKR	SPALI	SSP	STANLY
SUPER	SYNEX	THAI	TKS	TOPP	TRITN	TTA	UPF	UV	WIN	ZIGA

Level	
Certified	This level indicates practical participation with thoroughly examination in relation to the recommended procedures from the audit committee or the SEC's certified auditor, being a certified member of Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) or already passed examination to ensure independence from external parties.
Declared	This level indicates determination to participate in the Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC)

Disclaimer:

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, FSS International Investment Advisory Company Limited does not confirm, verify, or certify the accuracy and completeness of the assessment results.

Note: Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of June 24, 2019) are categorised into: 1) companies that have declared their intention to join CAC, and; 2) companies certified by CAC.

Source: The Securities and Exchange Commission, Thailand; * FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSS makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSS has no intention to solicit investors to buy or sell any security in this report. In addition, FSS does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 11.00	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Bangkok Dusit Medical Services	BDMS TB	THB 23.20	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Bumrungrad Hospital	BH TB	THB 143.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Bangkok Chain Hospital	BCH TB	THB 20.40	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Chularat Hospital	CHG TB	THB 3.74	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Thonburi Healthcare Group	THG TB	THB 33.25	HOLD	Downside risks to our DCF-based target price include 1) weak patient volume following the economic slowdown; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected expenses from new hospitals. Upside risk is big-lot sales of Jin Wellbeing County units.
Vibhavadi Medical Center	VIBHA TB	THB 2.22	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Ramkhamhaeng Hospital	RAM TB	THB 168.00	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited

FSSIA may incorporate the recommendations and target prices of companies currently covered by FSS Research into equity research reports, denoted by an 'FSS' before the recommendation. FSS Research is part of Finansia Syrus Securities Public Company Limited, which is the parent company of FSSIA.

All share prices are as at market close on 19-Oct-2021 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as $(\text{target price}^* - \text{current price}) / \text{current price}$.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.